Controlling homocysteine levels
To reduce the burden of patients and allow them to fully participate in life.
Orphan Technologies

Link to Clinical trial for classical homocystinuria

dedicated to understanding homocysteine

Link to Natural History Study about homocystinuria

Orphan Technologies is committed to reduce the burden of patients suffering from elevated homocysteine levels. OT-58, our lead drug development candidate, has been optimized as an enzyme therapy for classical homocystinuria, a genetic disease characterized by debilitating cardiovascular, skeletal, neurologic, and ophthalmologic complications. OT-58 is designed to reduce homocysteine levels via a targeted mechanism of action and may have therapeutic applications in other diseases.

watch video
“... after my brother had issues with his eyesight the eye doctor referred or entire family to a geneticist to be tested for homocystinuria...”
watch video
“... OT-58 is designed to help patients reduce their homocysteine levels and restore a normal lifestyle.”
watch video

October is #Homocystinuria Awareness month. @HCUNetworkAmerica  Show your support and share the #HCUAwareness Ribbon


Orphan Technologies interview on the HC&U podcast.